The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Aggressive Pituitary Tumors
Open accessAbstract
Pituitary adenomas are common intracranial tumors that are mainly considered as benign. Rarely, these tumors can exhibit an aggressive behavior, characterized by gross invasion of the surrounding tissues, resistance to conventional treatment leading to early and frequent recurrences. Even more rarely, pituitary tumors can give rise to cerebrospinal or systemic metastases qualifying as pituitary carcinomas according to the latest WHO definition. In the same classification, a subset of tumors with relatively distinct histopathological features was identified and defined as atypical adenomas designated to follow a more aggressive clinical course. This classification, although clinically useful, does not provide an accurate correlation between histopathological findings and the clinical behavior of these tumors, neither is it adequate to convey the precise features of ‘aggressive' tumors. Thus, ‘aggressive' pituitary adenomas need to be properly defined with clinical, radiological, histological and molecular markers in order to identify patients at increased risk of early recurrence or subsequent tumor progression. At present, no single marker or classification system of pituitary tumor aggressiveness exists, and clinically useful information in the literature is insufficient to guide diagnostic and therapeutic decisions. Treatment of patients with aggressive pituitary tumors is challenging since conventional treatments often fail, necessitating multiple surgical procedures with additional radiotherapy. Although traditional chemotherapy applied in other neuroendocrine tumors has not been shown to be efficacious, newer agents, particularly temozolomide, have shown promising results and are currently used despite the lack of data from a randomized prospective trial. Molecular targeted therapies such as mTOR and epidermal growth factor inhibitors have also been applied and might prove to be useful in the management of these patients. In the present review, we provide information regarding the epidemiology and clinical, histopathological and molecular features of aggressive pituitary tumors using recent employed definitions. In addition, we review currently employed therapeutic means providing a therapeutic algorithm and highlight the need to identify more specific disease-related and prognostic markers and the necessity for central registration of these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Clinical Implications of the p53 Tumor-Suppressor Gene
Harris, C. C., & Hollstein, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310283291807 · Cited by 1,330
Pituitary Adenomas with Invasion of the Cavernous Sinus Space
Knosp, E., Steiner, E., Kitz, K., & Matula, C. (1993) · Neurosurgery · doi:10.1097/00006123-199310000-00008 · Cited by 1,208
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Transphenoidal Microsurgery of the Normal and Pathological Pituitary: Chapter X
Hardy, J. (1969) · Neurosurgery · doi:10.1093/neurosurgery/16.cn_suppl_1.185 · Cited by 640
Saeger, W., Lüdecke, D. K., Buchfelder, M., Fahlbusch, R., Quabbe, H.-J., & Petersenn, S. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02326 · Cited by 583
Isolation and Characterization of a Pituitary Tumor-Transforming Gene (PTTG)
Pei, L. (1997) · Molecular Endocrinology · doi:10.1210/me.11.4.433 · Cited by 576
HYPOPRONOS, T. M. O., Trouillas, J., Roy, P., Sturm, N., Dantony, E., Cortet-Rudelli, C., Viennet, G., Bonneville, J.-F., Assaker, R., Auger, C., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1084-y · Cited by 545
Thyrotropin-Secreting Pituitary Tumors*
BECK-PECCOZ, P., BRUCKER-DAVIS, F., PERSANI, L., SMALLRIDGE, R. C., & WEINTRAUB, B. D. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-6-610 · Cited by 491
Pathogenesis of pituitary tumors
Melmed, S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.40 · Cited by 466
Thapar, K., Kovacs, K., Scheithauer, B. W., Stefaneanu, L., Horvath, E., Peter J., P., Murray, D., & Laws, E. R. (1996) · Neurosurgery · doi:10.1097/00006123-199601000-00024 · Cited by 462
The power and the promise of oncogene-induced senescence markers
Collado, M., & Serrano, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1884 · Cited by 404
miR‐15a and miR‐16‐1 down‐regulation in pituitary adenomas
Bottoni, A., Piccin, D., Tagliati, F., Luchin, A., Zatelli, M. C., & Degli Uberti, E. C. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20282 · Cited by 360
Meij, B. P., Lopes, M.-B. S., Ellegala, D. B., Alden, T. D., & Laws, E. R. (2002) · Journal of Neurosurgery · doi:10.3171/jns.2002.96.2.0195 · Cited by 327
Diagnosis and Management of Pituitary Carcinomas
Kaltsas, G. A., Nomikos, P., Kontogeorgos, G., Buchfelder, M., & Grossman, A. B. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2231 · Cited by 325
Self-citationThapar, K., Scheithauer, B. W., Kovacs, K., Pernicone, P. J., & Laws, E. R. (1996) · Neurosurgery · doi:10.1097/00006123-199604000-00027 · Cited by 321
Aggressive pituitary adenomas—diagnosis and emerging treatments
Di Ieva, A., Rotondo, F., Syro, L. V., Cusimano, M. D., & Kovacs, K. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.64 · Cited by 318
Beck-Peccoz, P., Lania, A., Beckers, A., Chatterjee, K., & Wemeau, J.-L. (2013) · European Thyroid Journal · doi:10.1159/000351007 · Cited by 283
Sex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study1
Delgrange, E., Trouillas, J., Maiter, D., Donckier, J., & Tourniaire, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4088 · Cited by 277
Pathobiology of Pituitary Adenomas and Carcinomas
Scheithauer, B. W., Gaffey, T. A., Lloyd, R. V., Sebo, T. J., Kovacs, K. T., Horvath, E., Yapcer, Ö., Young, W. F., Meyer, F. B., Kuroki, T., et al. (2006) · Neurosurgery · doi:10.1227/01.neu.0000223437.51435.6e · Cited by 262
Sheehan, J. P., Niranjan, A., Sheehan, J. M., Jane, J. A., Laws, E. R., Kondziolka, D., Flickinger, J., Landolt, A. M., Loeffler, J. S., & Lunsford, L. D. (2005) · Journal of Neurosurgery · doi:10.3171/jns.2005.102.4.0678 · Cited by 262
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
Fukuoka, H., Cooper, O., Ben-Shlomo, A., Mamelak, A., Ren, S.-G., Bruyette, D., & Melmed, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60417 · Cited by 254
Raverot, G., Sturm, N., de Fraipont, F., Muller, M., Salenave, S., Caron, P., Chabre, O., Chanson, P., Cortet-Rudelli, C., Assaker, R., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0644 · Cited by 228
Beck-Peccoz, P., Persani, L., Mannavola, D., & Campi, I. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.05.006 · Cited by 222
Pei, L., Melmed, S. K., Scheithauer, B. W., Kovács, K., Benedict, W. F., & Prager, D. (1995) · PubMed · Cited by 212
Alexandraki, K. I., Kaltsas, G. A., Isidori, A. M., Storr, H. L., Afshar, F., Sabin, I., Akker, S. A., Chew, S. L., Drake, W. M., Monson, J. P., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0921 · Cited by 203
Self-citationPituitary Carcinoma: Difficult Diagnosis and Treatment
Heaney, A. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2031 · Cited by 200
Bertagna, X., Pivonello, R., Fleseriu, M., Zhang, Y., Robinson, P., Taylor, A., Watson, C. E., Maldonado, M., Hamrahian, A. H., Boscaro, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2117 · Cited by 189
Temozolomide: a novel treatment for pituitary carcinoma
Lim, S., Shahinian, H., Maya, M. M., Yong, W., & Heaney, A. P. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70728-8 · Cited by 181
MicroRNAs Differentially Expressed in ACTH-Secreting Pituitary Tumors
Amaral, F. C., Torres, N., Saggioro, F., Neder, L., Machado, H. R., Silva, W. A., Moreira, A. C., & Castro, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1451 · Cited by 181
Long-term response of pituitary carcinoma to temozolomide
Fadul, C. E., Kominsky, A. L., Meyer, L. P., Kingman, L. S., Kinlaw, W. B., Rhodes, C. H., Eskey, C. J., & Simmons, N. E. (2006) · Journal of neurosurgery · doi:10.3171/jns.2006.105.4.621 · Cited by 167
Management of medically refractory prolactinoma
Molitch, M. E. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1270-8 · Cited by 165
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
McCormack, A. I., Wass, J. A. H., & Grossman, A. B. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02520.x · Cited by 161
Medical Treatment of Cushing's Disease
Feelders, R. A., & Hofland, L. J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3126 · Cited by 158
Bush, Z. M., Longtine, J. A., Cunningham, T. L., Schiff, D., Jane, J. A., Vance, M. L., Thorner, M. O., Laws, E. R., & Lopes, M. B. S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0441 · Cited by 153
p21 Cip1 restrains pituitary tumor growth
Chesnokova, V., Zonis, S., Kovács, K., Ben-Shlomo, A., Wawrowsky, K., Bannykh, S., & Melmed, S. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804810105 · Cited by 149
Jin, L. G., Qian, X., Kulig, E., Sanno, N., Scheithauer, B. W., Kovács, K., Young, W. F., & Lloyd, R. V. (1997) · Europe PMC (PubMed Central) · Cited by 144
Anti-VEGF therapy in pituitary carcinoma
Ortiz, L. D., Syro, L. V., Scheithauer, B. W., Erşen, A., Uribe, H., Fadul, C. E., Rotondo, F., Horváth, É., & Kovács, K. (2011) · Pituitary · doi:10.1007/s11102-011-0346-8 · Cited by 142
OUTCOMES AFTER REPEAT TRANSSPHENOIDAL SURGERY FOR RECURRENT CUSHING'S DISEASE
Patil, C. G., Veeravagu, A., Prevedello, D. M., Katznelson, L. J., Vance, M. L., & Laws, E. R. (2008) · Neurosurgery · doi:10.1227/01.neu.0000313117.35824.9f · Cited by 139
McCormack, A. I., McDonald, K. L., Gill, A. J., Clark, S. J., Burt, M. G., Campbell, K. A., Braund, W. J., Little, N., Cook, R., Grossman, A. B., et al. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03487.x · Cited by 136
Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma
Benveniste, R. J., King, W. A., Walsh, J. E., Lee, J. S., Delman, B. N., & Post, K. D. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.102.6.1004 · Cited by 134
HIROHATA, T., Asano, K., Ogawa, Y., Takano, S., Amano, K., Isozaki, O., Iwai, Y., Sakata, K., Fukuhara, N., Nishioka, H., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2924 · Cited by 129
Pituitary Hypoplasia inPttg−/−Mice Is Protective forRb+/−Pituitary Tumorigenesis
Chesnokova, V., Kovács, K., Castro, A.-V., Zonis, S., & Melmed, S. K. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0137 · Cited by 124
Hagen, C., Schroeder, H. D., Hansen, S., Hagen, C., & Andersen, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0389 · Cited by 124
Palumbo, T., Faucz, F. R., Azevedo, M., Xekouki, P., Iliopoulos, D., & Stratakis, C. A. (2013) · Oncogene · doi:10.1038/onc.2012.190 · Cited by 119
Korbonits, M., Chahal, H., Kaltsas, G., Jordan, S., URMANOVA, Y. M., Khalimova, Z., Harris, P. E., Farrell, W. E., Claret, F.-X., & Grossman, A. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.6.2635 · Cited by 119
Self-citationMGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy
Kovács, K., Scheithauer, B. W., Lombardero, M., McLendon, R. E., Syro, L. V., Uribe, H., Ortiz, L. D., & Penagos, L. C. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0279-5 · Cited by 118
Kelly, D. F. (2007) · Neurosurgical FOCUS · doi:10.3171/foc.2007.23.3.7 · Cited by 115
Role of stereotactic radiosurgery in the management of pituitary adenomas
Castinetti, F., Régis, J. M., Dufour, H., & Brue, T. C. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.4 · Cited by 112
Syro, L. V., Uribe, H., Penagos, L. C., Ortiz, L. D., Fadul, C. E., Horváth, É., & Kovács, K. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02653.x · Cited by 110
Kovács, K., Horváth, É., Syro, L. V., Uribe, H., Penagos, L. C., Ortiz, L. D., & Fadul, C. E. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.07.014 · Cited by 110
Pituitary Carcinoma: A Clinicopathological Review
Scheithauer, B. W., Yapıcıer, Ö., Kovács, K., Young, W. F., & Lloyd, R. V. (2005) · Neurosurgery · doi:10.1227/01.neu.0000157926.72826.db · Cited by 109
The pathophysiology of pituitary adenomas
Dworakowska, D., & Grossman, A. B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.05.004 · Cited by 109
Hussaini, I. M., Trotter, C., Zhao, Y., Abdel‐Fattah, R., Amos, S., Xiao, A., Agi, C. U., Redpath, G. T., Fang, Z., Leung, G., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060736 · Cited by 103
Trouillas, J., Daniel, L., Mp, G., Tong, S., Gouvernet, J., Jouanneau, E., Jan, M., Perrin, G., Fischer, G., Tabarin, A., et al. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.98.5.1084 · Cited by 100
Predictive Markers of Pituitary Adenoma Behavior
Kontogeorgos, G. (2006) · Neuroendocrinology · doi:10.1159/000095526 · Cited by 97
Management of aggressive pituitary adenomas and pituitary carcinomas
Heaney, A. P. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1413-6 · Cited by 97
Upregulation of myosin Va by Snail is involved in cancer cell migration and metastasis
Lan, L., Han, H., Zuo, H., Chen, Z., Du, Y., Zhao, W., Gu, J., & Zhang, Z. (2009) · International Journal of Cancer · doi:10.1002/ijc.24641 · Cited by 88
Zacharia, B. E., Gulati, A. P., Bruce, J. N., Carminucci, A. S., Wardlaw, S. L., Siegelin, M. D., Remotti, H. E., Lignelli, A., & Fine, R. L. (2013) · Neurosurgery · doi:10.1227/neu.0000000000000251 · Cited by 88
Qian, Z. R., Sano, T., Asa, S. L., Yamada, S., Horiguchi, H., Tashiro, T., Li, C. C., Hirokawa, M., Kovács, K., & Ezzat, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031489 · Cited by 83
Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists
Neff, L. M., Weil, M., Cole, A., Hedges, T. R., Shucart, W. A., Lawrence, D. P., Zhu, J., Tischler, A. S., & Lechan, R. M. (2007) · Pituitary · doi:10.1007/s11102-007-0014-1 · Cited by 80
High plasma proopiomelanocortin in aggressive adrenocorticotropin- secreting tumors
Raffin‐Sanson, M., Massias, J. F., Dumont, C., Raux-Demay, M. C., Proeschel, M. F., LUTON, J. P., & BERTAGNA, X. Y. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954027 · Cited by 74
Takeshita, A., Inoshita, N., Taguchi, M., Okuda, C., Fukuhara, N., Oyama, K., Ohashi, K., Sano, T., Takeuchi, Y., & Yamada, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0414 · Cited by 74
Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas
Duong, C. V., Emes, R. D., Wessely, F., Yacqub‐Usman, K., Clayton, R. N., & Farrell, W. E. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0251 · Cited by 74
Ezzat, S., Horváth, É., Kovács, K., et al. (1995) · Endocrine Pathology · doi:10.1007/bf02739875 · Cited by 68
Baldari, S., Ferraù, F., Alafaci, C., Herberg, A., Granata, F., Militano, V., Salpietro, F. M., Trimarchi, F., & Cannavò, S. (2012) · Pituitary · doi:10.1007/s11102-011-0373-5 · Cited by 64
Pack, S., Qin, L.-X., Pak, E. D., Wang, Y., Ault, D. O., Mannan, P., Jaikumar, S., Stratakis, C. A., Oldfield, E. H., Zhuang, Z., et al. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20162 · Cited by 55
Epigenetic change in pituitary tumorigenesis.
Farrell, W. E., & Clayton, R. N. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100323 · Cited by 55
Radiotherapy for Non-Functioning Pituitary Tumors—When and Under What Circumstances?
Gittoes, N. J. L. (2003) · Pituitary · doi:10.1023/b:pitu.0000004801.95086.e2 · Cited by 50
Lineage-Specific Restraint of Pituitary Gonadotroph Cell Adenoma Growth
Chesnokova, V., Zonis, S., Zhou, C., Ben-Shlomo, A., Wawrowsky, K., Toledano, Y., Tong, Y., Kovács, K., Scheithauer, B. W., & Melmed, S. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017924 · Cited by 50
Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma
Komor, J., Reubi, J. C., & Christ, E. (2013) · Pituitary · doi:10.1007/s11102-013-0494-0 · Cited by 50
Filopanti, M., Barbieri, A. M., Angioni, A. R., Colao, A. A. L., Gasco, V., Grottoli, S., Peri, A., Baglioni, S., Fustini, M. F., Pigliaru, F., et al. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.1 · Cited by 43
Oncogene-induced senescence in pituitary adenomas and carcinomas
Alexandraki, K., Khan, M. M., Chahal, H., Dalantaeva, N. S., Trivellin, G., Berney, D. M., Caron, P. J., POPOVIC, V. M., Pfeifer, M., Jordan, S., et al. (2012) · HORMONES · doi:10.14310/horm.2002.1358 · Cited by 38
Self-citationMatsuno, A., Murakami, M., Hoya, K., Yamada, S. M., Miyamoto, S., Yamada, S., Son, J.-H., Nishido, H., Ide, F., Nagashima, H., et al. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0050-z · Cited by 21
A differential diagnosis of inherited endocrine tumors and their tumor counterparts
Toledo, S. P. A., Lourenço, D. M., & Toledo, R. A. (2013) · Clinics · doi:10.6061/clinics/2013(07)24 · Cited by 16
Research works printed but not linked: 69
- 10.3171/jns.1986.64.3.0402 · doi:10.3171/jns.1986.64.3.0402
- 10.1007/s00401-005-1097-2 · doi:10.1007/s00401-005-1097-2
- 10.1530/EJE-13-1031 · doi:10.1530/eje-13-1031
- 10.1227/01.NEU.0000349930.66434.82 · doi:10.1227/01.neu.0000349930.66434.82
- 10.1227/00006123-199310000-00008 · doi:10.1227/00006123-199310000-00008 · Paper page
- 10.14310/horm.2002.1380 · doi:10.14310/horm.2002.1380
- 10.1007/s11102-008-0151-1 · doi:10.1007/s11102-008-0151-1
- 10.3171/2010.8.JNS10290 · doi:10.3171/2010.8.jns10290
- 10.5137/1019-5149.JTN.6828-12.1 · doi:10.5137/1019-5149.jtn.6828-12.1
- 10.1007/s00401-005-1093-6 · doi:10.1007/s00401-005-1093-6
- 10.1530/JME-12-0113 · doi:10.1530/jme-12-0113
- 10.1136/jcp.43.7.597 · doi:10.1136/jcp.43.7.597
- 10.1007/s00401-005-1095-4 · doi:10.1007/s00401-005-1095-4
- 10.1227/NEU.0b013e3181faa680 · doi:10.1227/neu.0b013e3181faa680
- 10.1016/j.humpath.2007.10.004 · doi:10.1016/j.humpath.2007.10.004
- 10.1210/jcem.85.10.6875 · doi:10.1210/jcem.85.10.6875
- 10.1111/j.1750-3639.2011.00476.x · doi:10.1111/j.1750-3639.2011.00476.x
- 10.1007/BF01403824 · doi:10.1007/bf01403824
- 10.1677/ERC-10-0018 · doi:10.1677/erc-10-0018
- 10.1159/000345673 · doi:10.1159/000345673
- 10.6061/clinics/2012(Sup01)09 · doi:10.6061/clinics/2012(sup01)09
- 10.1097/PAS.0b013e31815ade45 · doi:10.1097/pas.0b013e31815ade45
- 10.1210/jcem.87.6.8517 · doi:10.1210/jcem.87.6.8517
- 10.1210/mend.11.4.9911 · doi:10.1210/mend.11.4.9911 · Paper page
- 10.1111/j.1365-2265.2006.02630.x · doi:10.1111/j.1365-2265.2006.02630.x
- 10.1159/000343375 · doi:10.1159/000343375
- 10.1007/s11102-012-0434-4 · doi:10.1007/s11102-012-0434-4
- 10.1210/jcem.81.2.8636285 · doi:10.1210/jcem.81.2.8636285
- 10.1210/jcem.80.3.7883846 · doi:10.1210/jcem.80.3.7883846
- 10.2152/jmi.52.151 · DOI
- 10.1007/s11102-007-0066-2 · doi:10.1007/s11102-007-0066-2
- 10.1016/j.humpath.2013.05.020 · doi:10.1016/j.humpath.2013.05.020
- 10.1023/A:1009975009924 · doi:10.1023/a:1009975009924
- 10.1677/erc.0.0090103 · doi:10.1677/erc.0.0090103
- 10.3171/jns.1986.65.6.0733 · doi:10.3171/jns.1986.65.6.0733
- 10.1530/eje.0.1450137 · doi:10.1530/eje.0.1450137
- 10.1530/EJE-14-0249 · doi:10.1530/eje-14-0249
- 10.1177/147323001204000213 · doi:10.1177/147323001204000213
- 10.1111/j.1365-2265.2011.04163.x · doi:10.1111/j.1365-2265.2011.04163.x
- 10.1046/j.1365-2265.1998.00578.x · doi:10.1046/j.1365-2265.1998.00578.x
- 10.1111/j.1365-2265.1994.tb02456.x · doi:10.1111/j.1365-2265.1994.tb02456.x
- 10.1007/s11102-010-0221-z · doi:10.1007/s11102-010-0221-z
- 10.1007/s11102-008-0153-z · doi:10.1007/s11102-008-0153-z
- 10.1111/j.1365-2265.2012.04381.x · doi:10.1111/j.1365-2265.2012.04381.x
- 10.1016/j.nec.2006.04.001 · doi:10.1016/j.nec.2006.04.001
- 10.1016/j.ijrobp.2011.02.053 · doi:10.1016/j.ijrobp.2011.02.053
- 10.1227/01.NEU.0000255492.34063.32 · doi:10.1227/01.neu.0000255492.34063.32
- 10.1007/s11102-013-0541-x · doi:10.1007/s11102-013-0541-x
- 10.1530/EJE-09-0493 · doi:10.1530/eje-09-0493
- 10.1007/s11102-013-0540-y · doi:10.1007/s11102-013-0540-y
- 10.1210/jcem.83.12.5300 · doi:10.1210/jcem.83.12.5300
- 10.1111/j.1365-2265.1985.tb01076.x · doi:10.1111/j.1365-2265.1985.tb01076.x
- 10.1530/acta.0.1160347 · doi:10.1530/acta.0.1160347
- 10.1530/EJE-10-0629 · doi:10.1530/eje-10-0629
- 10.14310/horm.2002.1247 · doi:10.14310/horm.2002.1247
- 10.1007/s11060-011-0532-6 · doi:10.1007/s11060-011-0532-6
- 10.1007/s11102-009-0211-1 · doi:10.1007/s11102-009-0211-1
- 10.1055/s-0030-1253419 · doi:10.1055/s-0030-1253419
- 10.1210/jc.2009-1641 · DOI
- 10.1227/01.NEU.0000073783.96617.3A · doi:10.1227/01.neu.0000073783.96617.3a
- 10.1016/j.jocn.2009.05.013 · doi:10.1016/j.jocn.2009.05.013
- 10.1530/EJE-08-0557 · doi:10.1530/eje-08-0557
- 10.1100/tsw.2010.210 · doi:10.1100/tsw.2010.210
- 10.1227/01.NEU.0000339115.12803.4E · doi:10.1227/01.neu.0000339115.12803.4e
- 10.1155/2012/645914 · doi:10.1155/2012/645914
- 10.1007/s11102-011-0363-7 · doi:10.1007/s11102-011-0363-7
- 10.1227/NEU.0b013e318217161a · DOI
- 10.1007/s11102-010-0264-1 · doi:10.1007/s11102-010-0264-1
- 10.14310/horm.2002.1307 · doi:10.14310/horm.2002.1307
Cited by
Lee, Y. S., & Dutta, A. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092222 · Cited by 1,505
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
MicroRNA sponges: Progress and possibilities
Ebert, M. S., & Sharp, P. A. (2010) · RNA · doi:10.1261/rna.2414110 · Cited by 762
OncomiRs: the discovery and progress of microRNAs in cancers
Cho, W. C. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-60 · Cited by 719
Raverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., Trouillas, J., Dekkers, O. M., & _, _. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0796 · Cited by 595
Metadata
- Authors
- Chatzellis, E., Alexandraki, K. I., Androulakis, I. I., & Kaltsas, G.
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2015
- Volume
- 101
- Issue
- 2
- Pages
- 87-104
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W1607070363
- Cited by
- 572
- References
- 77
- FWCI
- 45.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.